Enterol, capsules 250 mg 30 pcs
€23.00 €19.17
Pharmacotherapeutic group: Antidiarrheal.
ATX code: A07FA02
Pharmacological properties:
Pharmacodynamics
Saccharomyces boulardii. CNCM I-745 is a live non-pathogenic yeast (deposited by the National Collection of Cultures and Microorganisms (CNCM), International Depository, Institut Pasteur, Paris).
The drug Saccharomyces boulardii is a probiotic and acts in the gastrointestinal tract as an anti-diarrheal microorganism.
The pharmacodynamics of Saccharomyces boulardii have been studied in various models in in
– has an antimicrobial effect due to its antagonistic effect against pathogenic and opportunistic microorganisms: Clostridium difficile, Candida albicans, Candida krusei, Candida pseudotropicalis, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella typhimurium, Yersinia enterocolitica, Escherichia coli, Shigella dysenteriae, Staphylococcus aureusand others, as well as Entamoeba histolytica and Lambliae;
–has antitoxic effects against bacterial cyto- and enterotoxins;
– increases intestinal enzymatic function;
A component of the cell wall of Saccharomyces boulardii mannitol is a substrate for pathogenic strains of Escherichia coli and Salmonella typhimuriumwhich causes their adhesion (attachment) to the surface of Saccharomyces boulardii and subsequent elimination from the body;
has a natural resistance to antibiotics.
Pharmacokinetics
Saccharomyces boulardii is not eubiotic, is not part of the microflora of the healthy human body. Saccharomyces boulardii is not absorbed, passes through the digestive tract unchanged, without colonization. The concentration of Saccharomyces boulardii in the intestine is maintained at a constant level during the period of administration of the drug. Saccharomyces boulardii is completely eliminated from the body within 2-5 days after discontinuation of the drug.
Indications
Treatment and prevention of diarrhea of any etiology in adults and children from 1 year old, including:
– intestinal dysbacteriosis (dysbiosis);
– acute infectious, viral or bacterial diarrhea;
– diarrhea caused by taking antibiotics (antibiotic-associated diarrhea);
– irritable bowel syndrome, enterocolitis;
– Travelers’ diarrhea;
– Diarrhea caused by Clostridium difficile, in combination with therapy with vancomycin or metronidazole;
/p>
– adverse gastrointestinal reactions during eradication therapy with Helicobacter pylori.
Composition
Active ingredient: Saccharomyces boulardii CNCM I-745 lyophilizate 250 mg.
Auxiliary substances: lactose monohydrate, magnesium stearate.
Capsule:titanium dioxide, gelatin.
How to take, the dosage
Interaction
Special Instructions
Diarrhea may be one symptom of a more serious primary disease.
If diarrhea persists after two days of administration, and if fever, blood, or mucus are found in stools, treatment should be reconsidered and oral or parenteral rehydration should be considered. In children under 2 years of age, consultation with the attending physician is recommended.
After stopping diarrhea, treatment with the drug may be continued for several days.
The use of the drug does not replace rehydration when necessary. The dosage for rehydration and the route of administration should be chosen according to the severity of the diarrhea and the patient’s age and condition.
In children from 1 to 2 years of age:Consultation with a physician may be necessary because of the possibility of primary disease. Rehydration may be the primary treatment for acute diarrhea in children and should be systematically reviewed.
In children aged 2 to 6 years:rehydration may be the primary treatment for acute diarrhea in children and should be systematically reviewed. Oral rehydration is given to prevent or treat dehydration. The use of ready-to-use preparations provided for this purpose is recommended.
In case of severe or prolonged diarrhea, severe vomiting, or refusal of oral rehydration, parenteral rehydration should be considered.
In adults and children over 6 years of age:If diarrhea persists after two days of taking the drug, treatment should be reconsidered and oral or parenteral rehydration should be considered.
Due to the yeast nature of Enterol®, very rare cases of fungemia have been reported (cultures of Saccharomyces have been isolated from blood), mostly in patients who had a central venous catheter, in patients who were extremely ill or had immunodeficiency states, which was often accompanied by fever (elevated body temperature). In most cases, the outcome was satisfactory after discontinuation of treatment, administration of antifungal therapy, and removal of the catheter, if necessary. However, in some patients whose condition was severe, the outcome was unfavorable.
Particular caution should be exercised when handling the drug in the presence of patients with central and peripheral venous catheters, even if they are not treated with Enterol®, care should be taken to avoid the risk of contamination by contaminated hands or airborne spread of microorganisms.
Preparations for administration of the drug by patients and opening capsules of Enterol ® should be done with medical gloves; in case of contact with the contents of the capsules, the gloves must be disposed of immediately after their use; hands must be thoroughly washed.
Influence on the ability to drive vehicles, machinery:
The use of Enterol® does not affect the ability to drive vehicles and engage in other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions.
Synopsis
Contraindications
Side effects
Skin and subcutaneous tissue disorders
Very rare: allergic reactions – itching, papular rash (urticaria), skin rash, local or distributed throughout the body (localized or generalized exanthema), facial edema (angioedema).
Disorders of the immune system
Very rare: anaphylactic reactions or anaphylactic shock.
Gastrointestinal tract disorders
Rare: flatulence;
Frequent unknown: constipation.
Infectious and parasitic diseases
Very rare: fungemia (in patients who have a central venous catheter installed, as well as in hospitalized patients, persons with immunodeficiency conditions (see “Special Instructions”).
Overdose
Pregnancy use
There are no or limited data on the use of Saccharomyces boulardii in pregnant women and during breastfeeding.
Saccharomyces boulardii is not absorbed from the gastrointestinal tract.
As a precautionary measure, it is preferable to evaluate the ratio of the expected benefit to the mother to the potential risk to the fetus and child before using the drug during pregnancy and while breastfeeding.
The physician should be consulted.
Weight | 0.070 kg |
---|---|
Shelf life | 3 years. Do not use after the date indicated on the package. |
Conditions of storage | At 15-25ºC, out of the reach of children. |
Manufacturer | Biocodex, France |
Medication form | capsules |
Brand | Biocodex |
Other forms…
Related products
Buy Enterol, capsules 250 mg 30 pcs with delivery to USA, UK, Europe and over 120 other countries.